$CVSA

Covista Inc. (CVSA): Results of Operations and Financial Condition

Covista Inc. (CVSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cvsa-20260806xex99d1.htm EX-99.1 Exhibit 99.1 Investor Contact: Jeremy Cohen Investor.Relations@Covista.com +1 312-906-6600 ​ Media Contact: Maureen Bender CovistaMedia@Covista.com +1 313-319-4732 Covista Announces Fiscal Year 2026 Results, Exceeds Financial Guidance; I

Original reporting
Published Aug 6, 2026, 8:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CVSA
Bullish
high confidence
Mentioned
$CVSA
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CVSABullishHigh
01

Why it matters

The 8-K provides both historical performance (Q4 and FY2026) and forward-looking targets (FY2027 revenue and adjusted EPS), which are direct inputs to valuation and positioning.

02

Market read

A fresh earnings and guidance package for CVSA, with explicit FY2027 ranges and enrollment momentum, is likely to be the dominant driver for short-term trading.

03

What to watch

Traders may underweight the quality of enrollment mix and any future regulatory approval timelines for new programs, which are mentioned but not quantified.

Relevance 7/10Novelty 9/10Timing: post-market today, guidance and FY2026 results released via 8-K

Background

Covista completed its prior three-year Growth with Purpose strategy and is transitioning to a Purpose at Scale operating model.

Company-level read

Ticker impact

$CVSABullishHigh confidence
Context

Covista reported FY2026 results and initiated FY2027 guidance, including revenue $2,050M to $2,090M and adjusted EPS $8.90 to $9.15.

Expected impact

Likely positive bias for CVSA as guidance implies continued growth and the company exceeded fiscal 2026 targets per the release.

Evidence & confidence

The filing includes concrete FY2026 financials (revenue, EPS, EBITDA) and explicit FY2027 revenue and adjusted EPS ranges, enabling traders to update models immediately.

Market effects

Healthcare education providers may see read-across on enrollment durability and profitability, especially for nursing and healthcare workforce pipelines.

Limited; primary impact is on US-listed higher-education equities tied to healthcare workforce demand.

Low; the disclosure is company-specific and US-focused.

Counterpoint

Enrollment growth and guidance may still be sensitive to regulatory and student-aid dynamics, so the market could focus on sustainability rather than the headline growth rates.

Key entities

  • Covista Inc.

    NYSE-listed healthcare educator reporting FY2026 results and initiating FY2027 guidance.

  • Chamberlain University

    Covista’s nursing-focused university segment, highlighted for enrollment growth and campus expansion.

  • Walden University

    Covista’s university segment highlighted for double-digit enrollment growth and new program enrollment.

  • Advocate Health

    Named as launching a strategic nursing collaboration delivered through Chamberlain University.

Related articles

$CVSAMedAI 8/10

Covista (CVSA) Stock Trades Up, Here Is Why

Covista (NYSE: CVSA) shares rose about 13% after the company reported Q2 2026 revenue of $501.4 million, up 9.7% year over year, and adjusted EPS of $2.09, about 10% above Wall Street estimates. Operating margin increased to 19% from 16.8%. Covista also issued full-year adjusted earnings guidance above consensus; shares closed around $140.91.

$CVSAMedAI 8/10

Covista’s (NYSE:CVSA) Q2 CY2026 Sales Top Estimates

Covista (NYSE:CVSA), formerly DeVry Education Group, reported Q2 CY2026 revenue of $501.4 million, up 9.7% year on year and 3.1% above Wall Street estimates, according to the company. It guided full-year revenue to about $2.07 billion. Non-GAAP EPS was $2.09, 10.4% above consensus, and analysts expect full-year EPS to rise from $8.25 to $8.75.

$SHOPMedAI 8/10

Shopify Was Supposed to Be an AI Casualty. Its AI-Referred Traffic Just Tripled.

Shopify (SHOP) reported Q2 results, citing AI-referred traffic to merchants’ storefronts that tripled year over year and orders that began with AI search also tripled. New buyers from AI channels placed orders at nearly twice the rate of other channels. Revenue rose 34% to $3.6B, GMV reached $115.6B, operating income rose 68% to $488M, and free cash flow was $654M.

$GPRKMed

Geopark Q2 Earnings Call Highlights

Geopark (NYSE:GPRK) reported Q2 earnings call updates. It plans $40m to $50m of Vaca Muerta investment in 2H 2026 after $55m in 1H, with 70% to 80% in Q3. Full-year lifting costs are guided at $17 to $19/bbl. Cash rose to $316m, net leverage fell to 1.2x EBITDA, and a $0.023/share quarterly dividend was declared.

$GRDNMed

Guardian Pharmacy Services Q2 Earnings Call Highlights

Guardian Pharmacy Services (GRDN) reported Q2 net income of $22.1M vs $8.8M a year earlier, including an $8.5M payer-dispute settlement recorded as other income. The company expects H2 revenue to fall low-single digits YoY due to IRA pricing reductions, with adjusted EBITDA margin stable in Q3 and seasonally higher in Q4. It also appointed Morris as COO and named a new CFO.

$GPNMed

Global Payments Q2 Earnings Call Highlights

Global Payments (NYSE:GPN) reported Q2 results and discussed its Worldpay integration and Genius point-of-sale rollout. Management guided for about 4.5% revenue growth in 2H, margins near 43%, and cited drivers including sales-force ramp and enterprise go-lives. Q2 adjusted net revenue by segment: SMB $1.51B, Enterprise $838M, Platforms $628M. Adjusted free cash flow was $687M; net leverage just below 3.5x.